A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives

      This paper is only available as a PDF. To read, Please Download here.


      With the recent introduction and growing popularity of Depo-Provera® Contraceptive Injection, concern about the potential for weight gain during treatment has been raised. The purpose of the present study was to determine whether or not Depo-Provera® Contraceptive Injection is associated with greater weight gain, and incidence thereof, than Norplant® implants or oral contraceptives. A retrospective chart review of patients seen at a state- and federally-funded clinic was conducted. Fifty women in each treatment group who met the study criteria were identified and included in the study evaluation. Mean one-year weight gain for subjects in each group was as follows: −2.0 pounds in the oral contraceptive group, −1.8 pounds in the Norplant® implants group, and +0.1 pounds in the Depo-Provera® Contraceptive Injection group. While results among treatment groups differed slightly, no significant weight change occurred in any of the treatment groups.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hatcher RA
        • Trussell J
        • Stewart F
        • et al.
        3rd ed. Contraceptive Technology 1994–1996. Irvingston Publishers, New York1994
      1. 3rd ed. Product Information, Depo-Provera Contraceptive Injection®. Upjohn Company, Kalamazoo, MI1994
        • Goldzieher JW
        • Moses LE
        • Averkin E
        • Scheel C
        • Taber BZ
        A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives.
        Fertil Steril. 1971; 22: 609-623
        • McQueen EG
        Hormonal steroid contraceptives. IV: Adverse reactions and management of the patient.
        Drugs. 1971; 2: 138-164
        • McQueen EG
        Hormonal steroid contraceptives: A further review of adverse reactions.
        Drugs. 1978; 16: 322-357
        • Carpenter S
        • Neinstein LS
        Weight gain in adolescent and young adult oral contraceptive users.
        J Adolesc Health Care. 1986; 7: 342-344
        • Woods ER
        • Grace E
        • Havens KK
        • Merola JL
        • Emans SJ
        Contraceptive compliance with a levonorgestrel triphasic and a norethindrone monophasic oral contraceptive in adolescent patients.
        Am J Obstet Gynecol. 1992; 166: 901-907
        • Woutersz TB
        • Korba VD
        Five-year, multicenter study of triphasic low-dose, combination oral contraceptive.
        Int J Fertil. 1988; 33: 406-410
        • Weber-Diehl F
        • Lehnert J
        • Lachnit U
        Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: A randomized, controlled trial.
        Contraception. 1993; 48: 291-301
        • Corson SL
        Efficacy and clinical profile of a new oral contraceptive containing norgestimate.
        Acta Obstet Gynecol Scand. 1990; 152 (suppl): 25-31
        • Chapdelaine A
        • Desmarais J-L
        • Derman RJ
        Clinical evidence of the minimal androgenic activity of norgestimate.
        Int J Fertil. 1989; 34: 347-352
        • Renier M
        • Buytaert P
        Open, prospective, multicenter trial with a new monophasic contraceptive combination containing gestodene.
        Contraception. 1991; 43: 413-421
        • Berenson AB
        • Wiemann CM
        Patient satisfaction and side effects with levonorgestrel implant (Norplant) use in adolescents 18 years of age or younger.
        Pediatrics. 1993; 92: 257-260
        • Cullins VE
        • Remsburg RE
        • Blumenthal PD
        • Huggins GR
        Comparison of adolescent and adult experiences with Norplant levonorgestrel contraceptive implants.
        Obstet Gynecol. 1994; 83: 1026-1032
        • Schwallie PC
        • Assenzo Jr,
        Contraceptive use-Efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days.
        Fertil Steril. 1973; 24: 331-339
        • World Health Organization
        A multicentred Phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive efficacy and side effects.
        Contraception. 1986; 34: 223-236
        • El Mahgoub S
        Body weight and cycle control of injectable contraceptives.
        J Reprod Med. 1980; 24: 119-126
        • Castle WM
        • Sapire KE
        • Howard KA
        Efficacy and acceptability of injectable medroxyprogesterone—A comparison of 3-monthly and 6-monthly regimens.
        S Afr Med J. 1978; 53: 842-845
        • Mukherjea M
        • Mukherjee P
        • Biswas R
        Long-term contraception with Depo-Provera: A clinical evaluation.
        Int J Fertil. 1980; 25: 122-126
        • Fajumi JO
        Alterations in blood lipids and side effects induced by Depo-Provera in Nigerian women.
        Contraception. 1983; 27: 161-175
        • Chinnatamby S
        A comparison of the long-acting contraceptive agents norethisterone oenanthate and medroxyprogesterone acetate.
        Aust New Zealand J Obstet Gynaecol. 1971; 11: 233-236
        • World Health Organization
        Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone oenanthate and medroxyprogesterone acetate. 2. Bleeding patterns and side effects.
        Contraception. 1978; 17: 395-407
        • World Health Organization
        Multinational comparative clinical trial of long-acting injectable contraceptives: Norethisterone enanthate given in two dosage regimens and medroxyprogesterone acetate. Final report.
        Contraception. 1983; 28: 1-20